Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma
The Fast Track Designation highlights the potential of EBC-129 to address critical unmet needs in pancreatic ductal adenocarcinoma (PDAC).
Updated clinical data from the ongoing Phase 1 study of EBC-129 will be presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO).
SINGAPORE, May 28, 2025 /CNW/ -- The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for EBC-129 for the treatment of pancreatic ductal adenocarcinoma (PDAC). EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. It is currently undergoing Phase 1 clinical trials for the treatment of patients with solid tumours with high unmet medical need.
The Fast Track Designation facilitates the expedited development of EBC-129, enabling more frequent engagement with the FDA to discuss the clinical development plan. It also provides potential eligibility for Priority Review and Accelerated Approval, as well as rolling review of any future Biologic License Application (BLA).
"The FDA's Fast Track Designation for EBC-129 underscores the promise of this novel ADC in addressing the critical need for expanded treatment options for PDAC patients and represents an important step in our efforts to accelerate its development. We view this as both a validation of our efforts and a responsibility to move decisively to advance EBC-129 as a new option to patients in need," said Professor Damian O'Connell, Chief Executive Officer of EDDC.
Updated clinical data from the ongoing Phase 1 study of EBC-129 will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from 30 May to 3 June 2025.
Presentation Details at ASCO 2025:
Title: Clinical activity of EBC-129, a first-in class, anti-N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a Phase 1 study
Rapid Oral Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Date and Time: Monday, June 2, 2025, 11:30 AM – 1:00 PM GMT-5
Abstract Number: 4018
Presenter: Assistant Professor Robert W. Lentz, MD, Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz School of Medicine
About EBC-129
EBC-129 is an ADC that targets a tumour-specific N256-glycosylation site conserved on CEACAM5 and CEACAM6. CEACAM5 and CEACAM6 are known to have functional importance in tumour formation, migration and metastasis. In the ongoing trial, the tumour-specific marker is found to be widely expressed in multiple solid tumour types, including gastric, oesophageal, pancreatic, lung, colorectal, and appendiceal cancers, based on an analytically validated immunohistochemistry (IHC) assay. The payload used in EBC-129 is monomethyl auristatin E (MMAE) which has been extensively tested and approved for clinical use in other marketed ADCs and has demonstrated synergy with PD-1 inhibitors. The ongoing Phase 1 trial of EBC-129 is assessing the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours. Enrolment for the PDAC cohort in the Phase 1 dose expansion study is now complete, while recruitment continues for the gastroesophageal adenocarcinoma (GEA) and IHC-positive cohorts.
For information about the trial, please visit Clinicaltrial.gov, trial identifier NCT05701527.
About the Experimental Drug Development Centre
The Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore's biomedical and clinical sciences R&D into innovative healthcare solutions. For more information about EDDC, please visit www.eddc.sg.
View original content to download multimedia:https://www.prnewswire.com/news-releases/experimental-drug-development-centre-granted-us-fda-fast-track-designation-for-antibody-drug-conjugate-ebc-129-to-treat-pancreatic-ductal-adenocarcinoma-302465707.html
SOURCE EXPERIMENTAL DRUG DEVELOPMENT CENTRE
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/28/c8001.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
2 hours ago
- CNN
Start your week smart: Coffee 101, Trump's tariffs, Wimbledon, ‘Superman' box office, Live Aid
5 Things Donald Trump Tariffs Food & drinkFacebookTweetLink Follow Exactly 40 years ago today, an estimated 1.5 billion people in more than 100 countries tuned in to watch Live Aid, a mega benefit concert held simultaneously in London and Philadelphia to raise funds for famine relief in Ethiopia. Dozens of music icons took to the stages throughout the day and night, but one of the most memorable performances almost didn't happen. Here's what else you need to know to start your week smart. Coffee — whether it's your drink of choice while you read 5 Things or your midday pick-me-up — is one of the world's most popular beverages. While coffee beans originated in ninth-century Ethiopia, the plant wasn't cultivated and brewed into the drink the world has come to know and love until the 15th century in Yemen, according to NESCAFÉ. Today, it's estimated that people worldwide drink around 2 billion cups of coffee daily, according to a 2019 study. 1️⃣ Brewing benefits: The peak of summer is here, and as most try to beat the heat, research suggests that for regular coffee drinkers, the beverage can be just as hydrating as water. Daily coffee consumption is also linked to aging with a sharp mind and lowering the risk of developing cardiometabolic diseases. 2️⃣ Java jitters: According to the US FDA, consuming more than 400 milligrams of caffeine (equivalent to four or five cups of coffee) is considered excessive for most adults. Too much caffeine can cause sleep disruptions and, in rare cases, can lead to caffeine intoxication. 3️⃣ A whole latte options: Starbucks may dominate the coffee market, but competition is brewing. Luckin Coffee, a fast-growing coffee chain that rose to popularity in China, recently opened two US locations. Other chains like Dutch Bros, 7 Brew and Black Rock Coffee Bar have built a loyal following targeting Gen Z drinkers with TikTok-worthy coffees and refreshers at affordable prices. 4️⃣ Coffeehouse culture: Coffee shops have long been known as 'third spaces' — spots where people can gather that are not home or work. In 17th-century London, coffee shops were known as 'penny universities' because they served as places of social exchange and the drink cost only 1 cent. 5️⃣ Coffee and the climate crisis: Experts call coffee a complex commodity. The crop is not only labor-intensive to produce but is also sensitive to environmental changes. Factors like severe weather and rising temperatures can impact coffee production and drive up costs for consumers. • Trump announces tariffs of 30% on Mexico and the European Union• FEMA removed dozens of Camp Mystic buildings from 100-year flood map before expansion, records show• Trump says he's considering revoking Rosie O'Donnell's citizenship, reigniting decades-long feud MondayIt's the beginning of 'Crypto Week' in Washington, DC. The House will consider the GENIUS Act, which would provide a framework for regulating stablecoins — a type of crypto asset that is tied to the value of another asset, such as the US dollar or gold. Stablecoins were initially created as a way for crypto investors to store their money, but have grown in popularity in recent years for their use in digital payments. Cryptocurrencies have had a major revival under President Donald Trump's second term, yet critics have pointed to the Trump family's ties to the crypto industry. TuesdayWe'll get the latest reading on inflation when the Bureau of Labor Statistics releases the Consumer Price Index for June. Prices crept slightly higher in the previous month; however, economists are warning that President Trump's sweeping trade policy of tacking steep tariffs on most goods that come into America will deliver a taxing blow to consumers via higher prices. ThursdayA national anti-Trump protest dubbed 'Good Trouble Lives On' is scheduled for July 17 — the anniversary of the 2020 passing of Civil Rights icon and Congressman John Lewis. Lewis famously called on Americans fighting for justice to create 'good trouble' in the name of redeeming the soul of America. Thursday is also the deadline for Harvard University to hand over documents about its financial aid practices, as part of a congressional probe into alleged tuition price-fixing in the Ivy League. House Judiciary Committee Chairman Jim Jordan issued a subpoena to Harvard last month demanding the documents. And 70 years ago, on July 17, 1955, Disneyland in Anaheim, California, opened its gates to the public. Get '5 things' in your inbox If your day doesn't start until you're up to speed on the latest headlines, then let us introduce you to your new favorite morning fix. Sign up here for the '5 Things' newsletter.🎧 Fighting 'FraudGPT'In this episode of the 'One Thing' podcast, CNN's David Rind speaks to David Maimon, head of fraud insights at SentiLink and professor of criminology at Georgia State University, about why law enforcement needs better tools to fight AI-generated scams. Listen here. Prev Next 📸 Check out more images from the week that was, curated by CNN Photos. 👀 At a glance …Wimbledon wraps up today when Carlos Alcaraz faces Jannik Sinner in the men's singles final. In the women's singles final on Saturday, Iga Świątek beat Amanda Anisimova 6-0, 6-0, the first time in the Open Era a woman has won the final without giving up a game. The 2025 FIFA Club World Cup Final is set for later today with Chelsea taking on Paris Saint-Germain at MetLife Stadium in New Jersey. Major League Baseball's All-Star Game, also known as the 'Midsummer Classic' is scheduled for Tuesday in Atlanta. The 153rd Open Championship — aka the British Open — tees off Thursday at Royal Portrush Golf Club in Northern Ireland. And the 2025 WNBA All-Star Game will be played Saturday in Indianapolis, which is Caitlin Clark's home turf. 📺 TV + streamingThe CNN Original Series, 'Live Aid: When Rock 'n' Roll Took On the World,' celebrates the definitive story of how two rock stars inspired the largest global music events in history. The four-part series premieres tonight at 9 p.m. ET/PT. 🍿 In theaters'I Know What You Did Last Summer' is a sequel/reboot of the 1997 slasher film of the same name. Once again, a group of pretty young people tries to cover up an accident, only to be stalked and killed by the evil twin of the Gorton's Fisherman. A few original cast members, including Jennifer Love Hewitt and Freddie Prinze Jr., are back to try and help the new kids survive. Also at the multiplex is 'Eddington,' a dark comedy billed as a contemporary Western starring Joaquin Phoenix, Emma Stone and Pedro Pascal. On the family-friendly front is the animated 'Smurfs,' featuring the voices of Rihanna, James Corden and Nick Offerman. And, of course, 'Superman' soared into theaters this weekend, and brought with it a wealth of cameos and fun references to its DC Comics origin. ('Superman' is distributed by Warner Bros. Pictures, which is owned by CNN's parent company, Warner Bros. Discovery.) 🧠 Looking for a challenge to start your week? Take CNN's weekly news quiz to see how much you remember! So far, 52% of fellow quiz fans have gotten eight or more questions right. How will you fare? 'Radio Ga Ga'Travel back 40 years in time to when Queen's Freddie Mercury got more than 70,000 fans at Wembley Stadium to clap along in unison. Today's edition of 5 Things Sunday was edited and produced by CNN's Meghan Pryce.
Newsweek
8 hours ago
- Newsweek
FDA Issues Risk Warning After Mushrooms Recalled Nationwide
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. Food and Drug Administration (FDA) has issued a national advisory and classified a recent mushroom recall as Class I, the agency's highest level risk designation, due to potential Listeria monocytogenes contamination. Newsweek contacted Hofood99 Inc via telephone for comment outside of usual working hours on Sunday and left a voicemail message. Why It Matters The Class I recall status indicates that the product poses a risk of causing serious health consequences or death if consumed. Listeria monocytogenes can lead to severe and sometimes fatal infections, especially during pregnancy, and for newborns, elderly adults, and people with weakened immune systems. Although no illnesses have been reported, the risk to public health is significant, prompting the warnings from the FDA. This incident highlights ongoing concerns surrounding food safety, especially in the distribution and handling of perishable produce. What to Know As reported by Newsweek, the firm-initiated recall affects enoki mushrooms distributed by Hofood99 Inc, located at 21903 56th Avenue Oakland Gardens, New York, 11364. The affected mushrooms were sold in 200‑gram green plastic bags and marked with UPC 6 976532 310051 on the back label; a picture of enoki mushrooms is outlined in green on the front of the package. The recall number is H-0261-2025. Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) The 90 boxes of affected product were shipped to retailers nationwide and tested positive for Listeria during routine sampling conducted by the Michigan Department of Agriculture. Consumers are advised not to eat the product and to either discard it or return it to the store where it was purchased for a full refund. Symptoms of Listeria infection may include high fever, muscle aches, nausea, diarrhoea, and in severe cases, complications such as meningitis or miscarriage. Consumers are advised to clean and sanitise refrigerators and any surfaces that may have come into contact with the recalled mushrooms, as the bacteria can survive and spread in cold environments. What People Are Saying The FDA in the original alert in part: "The contamination was discovered after samples were collected from a store in Michigan and subsequent analysis by Michigan Department of Agriculture & Rural Development (MDARD) Laboratory Division revealed the presence of Listeria monocytogenes." The FDA, as stated on its website: "A recall is a method of removing or correcting products that are in violation of laws administered by the Food and Drug Administration (FDA). Recall is a voluntary action that takes place because manufacturers and distributors carry out their responsibility to protect the public health and well-being from products that present a risk of injury or gross deception or are otherwise defective. What Happens Next Consumers with questions can contact Hofood99 Inc. at (917) 756‑9833 during business hours of 9:00 a.m. to 2:00 p.m., Monday to Friday. Further updates are available on the FDA's website. Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts.
Yahoo
11 hours ago
- Yahoo
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
Atai Life Sciences N.V. (NASDAQ:ATAI) is among the . Aegis Capital analysts have reaffirmed their Buy rating on Atai Life Sciences N.V. (NASDAQ:ATAI), with an unchanged price target of $8.00, following the favorable Phase 2b results of the BPL-003 treatment for the company's Treatment Resistant Depression (TRD). Around 193 depression patients, who didn't respond to previous treatment, were part of the Phase 2b trial testing three doses: 0.3 mg, 8 mg, and 12 mg. Not only the 8mg but also the 12mg dose showcased statistically significant improvement in an FDA-accepted measurement of depression, with a healthy side-effect profile. A close-up of a medical professional providing advice to a patient struggling with opioid use disorder. The research firm believes these robust results strengthen the company's efforts to proceed to a Phase 3 clinical program, which would result in marketing approval. Going forward, Atai Life Sciences N.V. (NASDAQ:ATAI) plans to schedule a post-Phase 2 meeting with the FDA, with the Phase 3 trial expected to begin only at the end of the upcoming year. Another noteworthy development is the company's recent $50 million private capital raise, which involved the sale of 18,264,840 common shares with 25% warrant coverage at the market price. Moves like these highlight Atai Life Sciences N.V. (NASDAQ:ATAI)'s capacity to raise cash when needed. Atai Life Sciences N.V. (NASDAQ:ATAI) is a German clinical-stage biopharmaceutical company that researches, develops, and markets mental health treatments in the United States, Germany, and Canada. With a market capitalization of $587.639 million, the company is committed to healing mental health disorders. While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
